Amyloid protein-induced sequestration of the eukaryotic ribosome: effect of stoichiometry and polyphenolic inhibitors

FEBS Lett. 2022 May;596(9):1190-1202. doi: 10.1002/1873-3468.14308. Epub 2022 Feb 14.

Abstract

Alzheimer's disease (AD) is characterized by the appearance of neurofibrillary tangles comprising of the Tau protein and aggregation of amyloid-β peptides (Aβ 1-40 and Aβ 1-42). A concomitant loss of the ribosomal population is also observed in AD-affected neurons. Our studies demonstrate that, similarly to Tau protein aggregation, in vitro aggregation of Aβ peptides in the vicinity of the yeast 80S ribosome can induce co-aggregation of ribosomal components. The RNA-stimulated aggregation of Aβ peptides and the Tau-K18 variant is dependent on the RNA:protein stoichiometric ratio. A similar effect of stoichiometry is also observed on the ribosome-protein co-aggregation process. Polyphenolic inhibitors of amyloid aggregation, such as rosmarinic acid and myricetin, inhibit RNA-stimulated Aβ and Tau-K18 aggregation and can mitigate the co-aggregation of ribosomal components.

Keywords: Alzheimer's disease; Tau protein; aggregation; amyloid-β; polyphenolic inhibitors; ribosomal RNA; ribosome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides* / metabolism
  • Amyloidogenic Proteins* / metabolism
  • Humans
  • Neurofibrillary Tangles
  • RNA
  • Ribosomes / metabolism
  • Saccharomyces cerevisiae* / metabolism
  • tau Proteins* / metabolism

Substances

  • Amyloid beta-Peptides
  • Amyloidogenic Proteins
  • tau Proteins
  • RNA